Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: A meta-analysis

Christos Hatzigeorgiou, Jeffrey L. Jackson

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Studies determining the association between hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) and bone metabolism are mixed. We conducted a systematic review to assess the potential impact of statins on fractures, bone mineral density and bone markers. We searched Medline, Embase, the Cochrane Library, and Federal Research in Progress (FEDRIP). Inclusion criteria consisted of human studies with measurable outcomes, which were rated as good or fair according to the United States Preventive Services Task Force (USPSTF) criteria. The effects of statins on bone mineral density (BMD), bone markers and fracture risk were independently extracted by two reviewers and were combined by use of a random-effects model. The 31 analyzed studies included 24 observational studies and seven randomized controlled trials. Overall, statin use was associated with fewer hip fractures (OR 0.60, 95% CI 0.45-0.78) and improved hip BMD (Z score 0.12, 95% CI 0.05-0.19), with a non-significant reduction in vertebral fractures and no effect on vertebral BMD. In subgroup analysis of studies that involved only women there was a reduction in hip fractures (OR 0.75, 95% CI 0.60-0.95) and improvement in hip BMD (Z score 0.11, 95% CI 0.04-0.18). Vertebral BMD was unchanged, and only one study reported on vertebral fractures, finding improvement. Statins had only small effects on bone markers, with a decrease in alkaline phosphatase [standardized mean difference (SMD) -0.18, 95% CI -0.34 to -0.01], an increase in NTX (SMD 0.39, 95% CI 0.07-0.71), with no effect on osteocalcin or CTX. The statistically significant improvement in hip fracture risk was seen only in case-control trials, not in either the eight prospective trials or the two randomized controlled trials (RCTs). Statins may have a beneficial impact on bone metabolism and fracture risk; randomized controlled trials are needed to explore this association.

Original languageEnglish (US)
Pages (from-to)990-998
Number of pages9
JournalOsteoporosis International
Volume16
Issue number8
DOIs
StatePublished - Jul 1 2005
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Osteoporosis
Meta-Analysis
Oxidoreductases
Bone Density
Hip Fractures
Pelvic Bones
Randomized Controlled Trials
Bone Fractures
Bone and Bones
Osteocalcin
Advisory Committees
Libraries
Observational Studies
Alkaline Phosphatase
Research

Keywords

  • Bone marker
  • Bone mineral density
  • Fracture
  • HMG-CoA reductase inhibitors
  • Meta-analysis
  • Osteoporosis
  • Statin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis : A meta-analysis. / Hatzigeorgiou, Christos; Jackson, Jeffrey L.

In: Osteoporosis International, Vol. 16, No. 8, 01.07.2005, p. 990-998.

Research output: Contribution to journalArticle

@article{9e5eb53fbabf4d2ebb2ab0da051e675d,
title = "Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: A meta-analysis",
abstract = "Studies determining the association between hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) and bone metabolism are mixed. We conducted a systematic review to assess the potential impact of statins on fractures, bone mineral density and bone markers. We searched Medline, Embase, the Cochrane Library, and Federal Research in Progress (FEDRIP). Inclusion criteria consisted of human studies with measurable outcomes, which were rated as good or fair according to the United States Preventive Services Task Force (USPSTF) criteria. The effects of statins on bone mineral density (BMD), bone markers and fracture risk were independently extracted by two reviewers and were combined by use of a random-effects model. The 31 analyzed studies included 24 observational studies and seven randomized controlled trials. Overall, statin use was associated with fewer hip fractures (OR 0.60, 95{\%} CI 0.45-0.78) and improved hip BMD (Z score 0.12, 95{\%} CI 0.05-0.19), with a non-significant reduction in vertebral fractures and no effect on vertebral BMD. In subgroup analysis of studies that involved only women there was a reduction in hip fractures (OR 0.75, 95{\%} CI 0.60-0.95) and improvement in hip BMD (Z score 0.11, 95{\%} CI 0.04-0.18). Vertebral BMD was unchanged, and only one study reported on vertebral fractures, finding improvement. Statins had only small effects on bone markers, with a decrease in alkaline phosphatase [standardized mean difference (SMD) -0.18, 95{\%} CI -0.34 to -0.01], an increase in NTX (SMD 0.39, 95{\%} CI 0.07-0.71), with no effect on osteocalcin or CTX. The statistically significant improvement in hip fracture risk was seen only in case-control trials, not in either the eight prospective trials or the two randomized controlled trials (RCTs). Statins may have a beneficial impact on bone metabolism and fracture risk; randomized controlled trials are needed to explore this association.",
keywords = "Bone marker, Bone mineral density, Fracture, HMG-CoA reductase inhibitors, Meta-analysis, Osteoporosis, Statin",
author = "Christos Hatzigeorgiou and Jackson, {Jeffrey L.}",
year = "2005",
month = "7",
day = "1",
doi = "10.1007/s00198-004-1793-0",
language = "English (US)",
volume = "16",
pages = "990--998",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "8",

}

TY - JOUR

T1 - Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis

T2 - A meta-analysis

AU - Hatzigeorgiou, Christos

AU - Jackson, Jeffrey L.

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Studies determining the association between hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) and bone metabolism are mixed. We conducted a systematic review to assess the potential impact of statins on fractures, bone mineral density and bone markers. We searched Medline, Embase, the Cochrane Library, and Federal Research in Progress (FEDRIP). Inclusion criteria consisted of human studies with measurable outcomes, which were rated as good or fair according to the United States Preventive Services Task Force (USPSTF) criteria. The effects of statins on bone mineral density (BMD), bone markers and fracture risk were independently extracted by two reviewers and were combined by use of a random-effects model. The 31 analyzed studies included 24 observational studies and seven randomized controlled trials. Overall, statin use was associated with fewer hip fractures (OR 0.60, 95% CI 0.45-0.78) and improved hip BMD (Z score 0.12, 95% CI 0.05-0.19), with a non-significant reduction in vertebral fractures and no effect on vertebral BMD. In subgroup analysis of studies that involved only women there was a reduction in hip fractures (OR 0.75, 95% CI 0.60-0.95) and improvement in hip BMD (Z score 0.11, 95% CI 0.04-0.18). Vertebral BMD was unchanged, and only one study reported on vertebral fractures, finding improvement. Statins had only small effects on bone markers, with a decrease in alkaline phosphatase [standardized mean difference (SMD) -0.18, 95% CI -0.34 to -0.01], an increase in NTX (SMD 0.39, 95% CI 0.07-0.71), with no effect on osteocalcin or CTX. The statistically significant improvement in hip fracture risk was seen only in case-control trials, not in either the eight prospective trials or the two randomized controlled trials (RCTs). Statins may have a beneficial impact on bone metabolism and fracture risk; randomized controlled trials are needed to explore this association.

AB - Studies determining the association between hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) and bone metabolism are mixed. We conducted a systematic review to assess the potential impact of statins on fractures, bone mineral density and bone markers. We searched Medline, Embase, the Cochrane Library, and Federal Research in Progress (FEDRIP). Inclusion criteria consisted of human studies with measurable outcomes, which were rated as good or fair according to the United States Preventive Services Task Force (USPSTF) criteria. The effects of statins on bone mineral density (BMD), bone markers and fracture risk were independently extracted by two reviewers and were combined by use of a random-effects model. The 31 analyzed studies included 24 observational studies and seven randomized controlled trials. Overall, statin use was associated with fewer hip fractures (OR 0.60, 95% CI 0.45-0.78) and improved hip BMD (Z score 0.12, 95% CI 0.05-0.19), with a non-significant reduction in vertebral fractures and no effect on vertebral BMD. In subgroup analysis of studies that involved only women there was a reduction in hip fractures (OR 0.75, 95% CI 0.60-0.95) and improvement in hip BMD (Z score 0.11, 95% CI 0.04-0.18). Vertebral BMD was unchanged, and only one study reported on vertebral fractures, finding improvement. Statins had only small effects on bone markers, with a decrease in alkaline phosphatase [standardized mean difference (SMD) -0.18, 95% CI -0.34 to -0.01], an increase in NTX (SMD 0.39, 95% CI 0.07-0.71), with no effect on osteocalcin or CTX. The statistically significant improvement in hip fracture risk was seen only in case-control trials, not in either the eight prospective trials or the two randomized controlled trials (RCTs). Statins may have a beneficial impact on bone metabolism and fracture risk; randomized controlled trials are needed to explore this association.

KW - Bone marker

KW - Bone mineral density

KW - Fracture

KW - HMG-CoA reductase inhibitors

KW - Meta-analysis

KW - Osteoporosis

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=23744495979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744495979&partnerID=8YFLogxK

U2 - 10.1007/s00198-004-1793-0

DO - 10.1007/s00198-004-1793-0

M3 - Article

C2 - 15744453

AN - SCOPUS:23744495979

VL - 16

SP - 990

EP - 998

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 8

ER -